Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis

Journal of Virology

Volumn 87, Issue 3, 2013, Pages 1454-1464

  de Wilde, Adriaan H ^a   Li, Yanhua ^b   van der Meer, Yvonne ^a   Vuagniaux, Grégoire ^c   Lysek, Robert ^c   Fang, Ying ^b   Snijder, Eric J ^a   van Hemert, Martijn J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SOUTH DAKOTA STATE UNIVERSITY   (United States)

^c DEBIOPHARM SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN INHIBITOR; CYCLOSPORIN A; DEBIO 064; GREEN FLUORESCENT PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTERIVIRUS; ARTERIVIRUS INFECTION; ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT; EQUINE VIRAL ARTERITIS VIRUS; FRACTIONATION; HUMAN; HUMAN CELL; IC 50; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROTEIN SYNTHESIS; REPORTER GENE; RNA SYNTHESIS; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS INTERFERENCE; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; ANTIVIRAL AGENTS; ARTERITIS VIRUS, EQUINE; CELL LINE; CYCLOPHILINS; CYCLOSPORINE; GENE KNOCKDOWN TECHNIQUES; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; INHIBITORY CONCENTRATION 50; LEPIDOPTERA; MICROBIAL SENSITIVITY TESTS; PORCINE RESPIRATORY AND REPRODUCTIVE SYNDROME VIRUS; RNA, VIRAL; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84873045603     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02078-12     Document Type: Article

References (60)

1. Nagy PD, Pogany J. 2012. The dependence of viral RNA replication on co-opted host factors. Nat. Rev. Microbiol. 10:137-149.
2. Kellam P. 2006. Attacking pathogens through their hosts. Genome Biol. 7:201. doi:10.1186/gb-2006-7-1-201.
3. Schwegmann A, Brombacher F. 2008. Host-directed drug targeting of factors hijacked by pathogens. Sci. Signal. 1:re8. doi:10.1126/scisignal .129re8.
4. Bose S, Mathur M, Bates P, Joshi N, Banerjee AK. 2003. Requirement for cyclophilin A for the replication of vesicular stomatitis virus New Jersey serotype. J. Gen. Virol. 84:1687-1699.
5. Briggs CJ, Ott DE, Coren LV, Oroszlan S, Tozser J. 1999. Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV-1. Arch. Virol. 144:2151-2160.
6. Kambara H, Tani H, Mori Y, Abe T, Katoh H, Fukuhara T, Taguwa S, Moriishi K, Matsuura Y. 2011. Involvement of cyclophilin B in the replication of Japanese encephalitis virus. Virology 412:211-219.
7. Nakagawa M, Sakamoto N, Enomoto N, Tanabe Y, Kanazawa N, Koyama T, Kurosaki M, Maekawa S, Yamashiro T, Chen CH, Itsui Y, Kakinuma S, Watanabe M. 2004. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem. Biophys. Res. Commun. 313:42-47.
8. Qing M, Yang F, Zhang B, Zou G, Robida JM, Yuan Z, Tang H, Shi PY. 2009. Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein. Antimicrob. Agents Chemother. 53:3226-3235.
9. de Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y, Thiel V, Narayanan K, Makino S, Snijder EJ, van Hemert MJ. 2011. Cyclosporin A inhibits the replication of diverse coronaviruses. J. Gen. Virol. 92:2542-2548.
10. Pfefferle S, Schopf J, Kogl M, Friedel CC, Muller MA, Carbajo-Lozoya J, Stellberger T, von Dall'armi E, Herzog P, Kallies S, Niemeyer D, Ditt V, Kuri T, Zust R, Pumpor K, Hilgenfeld R, Schwarz F, Zimmer R, Steffen I, Weber F, Thiel V, Herrler G, Thiel HJ, Schwegmann-Wessels C, Pohlmann S, Haas J, Drosten C, von Brunn A. 2011. The SARScoronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog. 7:e1002331. doi:10.1371 /journal.ppat.1002331.
11. Tanaka Y, Sato Y, Osawa S, Inoue M, Tanaka S, Sasaki T. 2012. Suppression of feline coronavirus replication in vitro by cyclosporin A. Vet. Res. 43:41.
12. Barik S. 2006. Immunophilins: for the love of proteins. Cell. Mol. Life Sci. 63:2889-2900.
13. Davis TL, Walker JR, Campagna-Slater V, Finerty PJ, Paramanathan R, Bernstein G, MacKenzie F, Tempel W, Ouyang H, Lee WH, Eisenmesser EZ, Dhe-Paganon S. 2010. Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases. PLoS Biol. 8:e1000439. doi:10.1371/journal.pbio.1000439.
14. Nagy PD, Wang RY, Pogany J, Hafren A, Makinen K. 2011. Emerging picture of host chaperone and cyclophilin roles in RNA virus replication. Virology 411:374-382.
15. Tedesco D, Haragsim L. 2012. Cyclosporine: a review. J. Transplant. 2012:230386. doi:10.1155/2012/230386.
16. Flisiak R, Feinman SV, Jablkowski M, Horban A, Kryczka W, Pawlowska M, Heathcote JE, Mazzella G, Vandelli C, Nicolas-Metral V, Grosgurin P, Liz JS, Scalfaro P, Porchet H, Crabbe R. 2009. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 49:1460-1468.
17. Flisiak R, Horban A, Gallay P, Bobardt M, Selvarajah S, Wiercinska-Drapalo A, Siwak E, Cielniak I, Higersberger J, Kierkus J, Aeschlimann C, Grosgurin P, Nicolas-Metral V, Dumont JM, Porchet H, Crabbe R, Scalfaro P. 2008. The cyclophilin inhibitor Debio-025 shows potent antihepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 47:817-826.
18. Lawitz E, Godofsky E, Rouzier R, Marbury T, Nguyen T, Ke J, Huang M, Praestgaard J, Serra D, Evans TG. 2011. Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy. Antiviral Res. 89:238-245.
19. de Groot RJ, Cowley JA, Enjuanes L, Faaberg KS, Perlman S, Rottier PJ, Snijder EJ, Ziebuhr J, Gorbalenya AE. 2012. Order of Nidovirales, p 785-795. In King A, Adams M, Carstens E, Lefkowitz EJ (ed), Virus taxonomy, the 9th Report of the International Committee on Taxonomy of Viruses. Academic Press, New York, NY.
20. Holtkamp DJ, Kliebenstein JB, Neumann EJ, Zimmerman JJ, Rotto H, Yoder TK, Wang C, Yeske P, Mowrer C, Haley C. 2011. Abstr. 2011 Int. PRRS Symp., Chicago, IL, abstr. 86.
21. Snijder EJ, Spaan WJM. 2007. Arteriviruses, p 1337-1355. In Knipe DM, et al. (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
22. Gorbalenya AE, Enjuanes L, Ziebuhr J, Snijder EJ. 2006. Nidovirales: evolving the largest RNA virus genome. Virus Res. 117:17-37.
23. Pasternak AO, Spaan WJ, Snijder EJ. 2006. Nidovirus transcription: how to make sense? J. Gen. Virol. 87:1403-1421.
24. Fang Y, Snijder EJ. 2010. The PRRSV replicase: exploring the multifunctionality of an intriguing set of nonstructural proteins. Virus Res. 154:61-76.
25. Knoops K, Barcena M, Limpens RW, Koster AJ, Mommaas AM, Snijder EJ. 2012. Ultrastructural characterization of arterivirus replication structures: reshaping the endoplasmic reticulum to accommodate viral RNA synthesis. J. Virol. 86:2474-2487.
26. van der Meer Y, van Tol H, Krijnse Locker J, Snijder EJ. 1998. ORF1aencoded replicase subunits are involved in the membrane association of the arterivirus replication complex. J. Virol. 72:6689-6698.
27. van Hemert MJ, de Wilde AH, Gorbalenya AE, Snijder EJ. 2008. The in vitro RNA synthesizing activity of the isolated arterivirus replication/ transcription complex is dependent on a host factor. J. Biol. Chem. 283: 16525-16536.
28. Nedialkova DD, Gorbalenya AE, Snijder EJ. 2010. Arterivirus Nsp1 modulates the accumulation of minus-strand templates to control the relative abundance of viral mRNAs. PLoS Pathog. 6:e1000772. doi:10 .1371/journal.ppat.1000772.
29. de Vries AA, Chirnside ED, Horzinek MC, Rottier PJ. 1992. Structural proteins of equine arteritis virus. J. Virol. 66:6294-6303.
30. Kim HS, Kwang J, Yoon IJ, Joo HS, Frey ML. 1993. Enhanced replication of porcine reproductive and respiratory syndrome (PRRS) virus in a homogeneous subpopulation of MA-104 cell line. Arch. Virol. 133:477-483.
31. Kamitani W, Narayanan K, Huang C, Lokugamage K, Ikegami T, Ito N, Kubo H, Makino S. 2006. Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation. Proc. Natl. Acad. Sci. U. S. A. 103:12885-12890.
32. Bryans JT, Crowe ME, Doll ER, McCollum WH. 1957. Isolation of a filterable agent causing arteritis of horses and abortion by mares; its differentiation from the equine abortion (influenza) virus. Cornell Vet. 47: 3-41.
33. van den Born E, Posthuma CC, Knoops K, Snijder EJ. 2007. An infectious recombinant equine arteritis virus expressing green fluorescent protein from its replicase gene. J. Gen. Virol. 88:1196-1205.
34. Fang Y, Rowland RR, Roof M, Lunney JK, Christopher-Hennings J, Nelson EA. 2006. A full-length cDNA infectious clone of North American type 1 porcine reproductive and respiratory syndrome virus: expression of green fluorescent protein in the Nsp2 region. J. Virol. 80:11447-11455.
35. Sun Z Li Y, Ransburgh R, Snijder EJ, Fang Y. 2012. Nonstructural protein 2 of porcine reproductive and respiratory syndrome virus inhibits the antiviral function of interferon-stimulated gene 15. J. Virol. 86:3839-3850.
36. Pedersen KW, van der Meer Y, Roos N, Snijder EJ. 1999. Open reading frame 1a-encoded subunits of the arterivirus replicase induce endoplasmic reticulum-derived double-membrane vesicles which carry the viral replication complex. J. Virol. 73:2016-2026.
37. MacLachlan NJ, Balasuriya UB, Hedges JF, Schweidler TM, McCollum WH, Timoney PJ, Hullinger PJ, Patton JF. 1998. Serologic response of horses to the structural proteins of equine arteritis virus. J. Vet. Diagn. Invest. 10:229-236.
38. Knoops K, Swett-Tapia C, van den Worm SH, Te Velthuis AJ, Koster AJ, Mommaas AM, Snijder EJ, Kikkert M. 2010. Integrity of the early secretory pathway promotes, but is not required for, severe acute respiratory syndrome coronavirus RNA synthesis and virus-induced remodeling of endoplasmic reticulum membranes. J. Virol. 84:833-846.
39. Schreiber SL, Crabtree GR. 1992. The mechanism of action of cyclosporin A and FK506. Immunol. Today 13:136-142.
40. Hopkins S, Dimassimo B, Rusnak P, Heuman D, Lalezari J, Sluder A, Scorneaux B, Mosier S, Kowalczyk P, Ribeill Y, Baugh J, Gallay P. 2012. The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection. J. Hepatol. 57:47-54.
41. Wenger R, Mutter M, Garrouste P, Lysek R, Turpin O, Vuagniaux G, Nicolas V, Novaroli Zanolari L, Crabbé R. November 2009. Cycloundecadepsipeptide compounds and use of said compounds as a medicament. Patent WO 2010/052559.
42. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. 2003. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38:1282-1288.
43. Damaso CR, Keller SJ. 1994. Cyclosporin A inhibits vaccinia virus replication in vitro. Arch. Virol. 134:303-319.
44. Chatterji U, Lim P, Bobardt MD, Wieland S, Cordek DG, Vuagniaux G, Chisari F, Cameron CE, Targett-Adams P, Parkinson T, Gallay PA. 2010. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J. Hepatol. 53:50-56.
45. Fernandes F, Ansari IU, Striker R. 2010. Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A. PLoS One 5:e9815. doi:10.1371/journal.pone.0009815.
46. Gaither LA, Borawski J, Anderson LJ, Balabanis KA, Devay P, Joberty G, Rau C, Schirle M, Bouwmeester T, Mickanin C, Zhao S, Vickers C, Lee L, Deng G, Baryza J, Fujimoto RA, Lin K, Compton T, Wiedmann B. 2010. Multiple cyclophilins involved in different cellular pathways mediate HCV replication. Virology 397:43-55.
47. Coelmont L, Hanoulle X, Chatterji U, Berger C, Snoeck J, Bobardt M, Lim P, Vliegen I, Paeshuyse J, Vuagniaux G, Vandamme AM, Bartenschlager R, Gallay P, Lippens G, Neyts J. 2010. DEB025 (alisporivir) inhibits hepatitisCvirus replication by preventing a cyclophilinAinduced cis-trans isomerisation in domain II of NS5A. PLoS One 5:e13687. doi:10 .1371/journal.pone.0013687.
48. Foster TL, Gallay P, Stonehouse NJ, Harris M. 2011. Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner. J. Virol. 85:7460-7464.
49. Chatterji U, Bobardt M, Selvarajah S, Yang F, Tang H, Sakamoto N, Vuagniaux G, Parkinson T, Gallay P. 2009. The isomerase active site of cyclophilin A is critical for hepatitisCvirus replication. J. Biol. Chem. 284:16998-17005.
50. Liu Z, Yang F, Robotham JM, Tang H. 2009. Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J. Virol. 83:6554-6565.
51. Kaul A, Stauffer S, Berger C, Pertel T, Schmitt J, Kallis S, Zayas M, Lohmann V, Luban J, Bartenschlager R. 2009. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog. 5:e1000546. doi:10 .1371/journal.ppat.1000546.
52. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, Shimotohno K. 2005. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol. Cell 19:111-122.
53. Castro AP, Carvalho TM, Moussatche N, Damaso CR. 2003. Redistribution of cyclophilin A to viral factories during vaccinia virus infection and its incorporation into mature particles. J. Virol. 77:9052-9068.
54. Liu X, Sun L, Yu M, Wang Z, Xu C, Xue Q, Zhang K, Ye X, Kitamura Y, Liu W. 2009. Cyclophilin A interacts with influenza A virus M1 protein and impairs the early stage of the viral replication. Cell. Microbiol. 11: 730-741.
55. Luo C, Luo H, Zheng S, Gui C, Yue L, Yu C, Sun T, He P, Chen J, Shen J, Luo X, Li Y, Liu H, Bai D, Yang Y, Li F, Zuo J, Hilgenfeld R, Pei G, Chen K, Shen X, Jiang H. 2004. Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A. Biochem. Biophys. Res. Commun. 321:557-565.
56. Almazan F, Galan C, Enjuanes L. 2004. The nucleoprotein is required for efficient coronavirus genome replication. J. Virol. 78:12683-12688. 57. Schelle B, Karl N, Ludewig B, Siddell SG, Thiel V. 2006. Nucleocapsid protein expression facilitates coronavirus replication. Adv. Exp. Med. Biol. 581:43-48.
57. Schelle B, Karl N, Ludewig B, Siddell SG, Thiel V. 2006. Nucleocapsid protein expression facilitates coronavirus replication. Adv. Exp. Med. Biol. 581:43-48.
58. van der Meer Y, Snijder EJ, Dobbe JC, Schleich S, Denison MR, Spaan WJ, Krijnse Locker J. 1999. Localization of mouse hepatitis virus nonstructural proteins and RNA synthesis indicates a role for late endosomes in viral replication. J. Virol. 73:7641-7657.
59. Pang X, Zhang M, Zhou L, Xie F, Lu H, He W, Jiang S, Yu L, Zhang X. 2011. Discovery of a potent peptidic cyclophilin A inhibitor Trp-Gly-Pro. Eur. J. Med. Chem. 46:1701-1705.
60. Puyang X, Poulin DL, Mathy JE, Anderson LJ, Ma S, Fang Z, Zhu S, Lin K, Fujimoto R, Compton T, Wiedmann B. 2010. Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors. Antimicrob. Agents Chemother. 54:1981-1987.